SlideShare a Scribd company logo
FIP-WHO META Istanbul, Turkey September 5, 2009 1
Normita D. Leyesa, RPh, MS
President, Philippine Pharmacists Association
MeTA Council Member
Transparency and PharmaceuticalTransparency and Pharmaceutical
Practice from a MeTA Country:Practice from a MeTA Country:
The MeTA Philippines Country ReportThe MeTA Philippines Country Report
1
FIP-WHO META Istanbul, Turkey September 5, 2009 2
Medicine Transparency AllianceMedicine Transparency Alliance
(MeTA) initiative proposes to(MeTA) initiative proposes to
improve accessimprove access to medicinesto medicines
throughthrough transparencytransparency andand
accountabilityaccountability..
FIP-WHO META Istanbul, Turkey September 5, 2009 33
The Philippines WorkThe Philippines Work
Plan for the Phase IPlan for the Phase I
2009-20102009-2010
Objective:Objective:
Provide adequate information that
would strengthen decision-making and
implementation of processes along the
medicines registration, selection,
procurement, and use.
FIP-WHO META Istanbul, Turkey September 5, 2009 4
Preparation ofPreparation of
the Work Planthe Work Plan
 Identification of priority areas for MeTAIdentification of priority areas for MeTA
intervention by scoping visits, consultations, andintervention by scoping visits, consultations, and
stakeholder mappingstakeholder mapping
 Identification of areas supported by otherIdentification of areas supported by other
international development partners andinternational development partners and
stakeholdersstakeholders
 Line-up of activities and allocated budget wereLine-up of activities and allocated budget were
finally deliberated and approvedfinally deliberated and approved
FIP-WHO META Istanbul, Turkey September 5, 2009 5
Three Key Points ofThree Key Points of
Phase IPhase I
1.1. Country structure and commitmentCountry structure and commitment
2.2. Transparency: disclosure, data collectionTransparency: disclosure, data collection
and analysisand analysis
3.3. Accountability: multi-stakeholderAccountability: multi-stakeholder
approach and good governanceapproach and good governance
FIP-WHO META Istanbul, Turkey September 5, 2009 6
2009-20102009-2010
Strategic Work PlanStrategic Work Plan
 Developing Information on Prices, Availability,Developing Information on Prices, Availability,
Financing Mechanisms and Rational Drug UseFinancing Mechanisms and Rational Drug Use
 Generating Information to Improve Quality ofGenerating Information to Improve Quality of
PharmaceuticalsPharmaceuticals
 Setting up Systems for Transparency in MedicinesSetting up Systems for Transparency in Medicines
Registration, Selection, Procurement and UsageRegistration, Selection, Procurement and Usage
 Supporting Transparency Agenda in DecentralizedSupporting Transparency Agenda in Decentralized
SystemsSystems
 Preparation of Budget for the ActivitiesPreparation of Budget for the Activities
FIP-WHO META Istanbul, Turkey September 5, 2009 7
KEY OUTCOMESKEY OUTCOMES
FIP-WHO META Istanbul, Turkey September 5, 2009 8
Key Outcome 1:Key Outcome 1:
Available information onAvailable information on
medicines quality, registration,medicines quality, registration,
access, promotions, and rationalaccess, promotions, and rational
drug usedrug use
 Analysis of existing pharmaceutical data (ongoing)Analysis of existing pharmaceutical data (ongoing)
 Conduct of Level II and III Survey on medicinesConduct of Level II and III Survey on medicines
(ongoing)(ongoing)
 Assessment of Public SectorAssessment of Public Sector
– Procurement (including PITC) of medicinesProcurement (including PITC) of medicines
– Design ofDesign of ee-procurement system-procurement system
– Assessment of the current systems for financingAssessment of the current systems for financing
medicines for the poor (TOR)medicines for the poor (TOR)
 Survey of quality of medicines using the “FDA in aSurvey of quality of medicines using the “FDA in a
suitcase”suitcase”
 Study on medicines promotion and advertisementStudy on medicines promotion and advertisement
(TOR)(TOR)
FIP-WHO META Istanbul, Turkey September 5, 2009 9
Key Outcome 2:Key Outcome 2:
Setting up of informationSetting up of information
structures and systemsstructures and systems
 Improvement of the medicines registrationImprovement of the medicines registration
 FDA websiteFDA website
 Philippine National Drug Formulary WebsitePhilippine National Drug Formulary Website
 Support to the implementation of the ElectronicSupport to the implementation of the Electronic
Essential Drug Price Monitoring System (E-EDPMS) atEssential Drug Price Monitoring System (E-EDPMS) at
the regional and provincial levelsthe regional and provincial levels
 Development of systems for monitoring andDevelopment of systems for monitoring and
evaluation of ethical practices of industry and theevaluation of ethical practices of industry and the
medical professionmedical profession
 Development and testing of monitoring tools forDevelopment and testing of monitoring tools for
prescription auditsprescription audits
FIP-WHO META Istanbul, Turkey September 5, 2009 10
Key Outcome 3:Key Outcome 3:
Improvement of technicalImprovement of technical
capacity for disclosure, analysis, andcapacity for disclosure, analysis, and
the use of information and evidencethe use of information and evidence
 Pharmaceutical Management and Good GovernancePharmaceutical Management and Good Governance
Course for LGU Health Managers and Local ChiefCourse for LGU Health Managers and Local Chief
ExecutivesExecutives
 National Good Governance in Medicines AwardsNational Good Governance in Medicines Awards
 Strengthening of Drug Therapeutic Committees (DTC) atStrengthening of Drug Therapeutic Committees (DTC) at
Regional and Provincial levelsRegional and Provincial levels
 Technical capacity building for DTCsTechnical capacity building for DTCs
 Development of tools for monitoring/evaluation of DTCsDevelopment of tools for monitoring/evaluation of DTCs
 Piloting of the Pharmaceutical Bench BookPiloting of the Pharmaceutical Bench Book
FIP-WHO META Istanbul, Turkey September 5, 2009 11
Key Outcome 4:Key Outcome 4:
Setting up mechanism forSetting up mechanism for
advocacy and participation inadvocacy and participation in
decision making processesdecision making processes
 MeTA Roundtable discussionsMeTA Roundtable discussions
 PublicationsPublications
– Development of the MeTA WebsiteDevelopment of the MeTA Website
– Publication of Proceedings for MeTA ForumPublication of Proceedings for MeTA Forum
– Publication of Baseline AssessmentsPublication of Baseline Assessments
 Annual MeTA ForumAnnual MeTA Forum
FIP-WHO META Istanbul, Turkey September 5, 2009 12
Key Outcome 5:Key Outcome 5:
Sustaining a Multi-stakeholderSustaining a Multi-stakeholder
CollaborationCollaboration
 MeTA Council and Secretariat OperationsMeTA Council and Secretariat Operations
 Support to Civil Society OrganizationsSupport to Civil Society Organizations
– Coalition for Health Advocacy and TransparencyCoalition for Health Advocacy and Transparency
FIP-WHO META Istanbul, Turkey September 5, 2009 13
““The challenges in transparency andThe challenges in transparency and
accountability on medicine registration,accountability on medicine registration,
selection, procurement, and use in theselection, procurement, and use in the
Philippines are enormous.Philippines are enormous.
These can be summed up into two:These can be summed up into two: non-non-
accessibility of dataaccessibility of data to policy, decisionto policy, decision
makers, and consumers and themakers, and consumers and the lack oflack of
tools and structurestools and structures for adequatefor adequate
reporting, disclosure and feedback.”reporting, disclosure and feedback.”
FIP-WHO META Istanbul, Turkey September 5, 2009 14
With the assistance of MeTAWith the assistance of MeTA
International, and the Department ofInternational, and the Department of
International Development (DFID) UK,International Development (DFID) UK,
and the support of the World Healthand the support of the World Health
Organization, we will be able toOrganization, we will be able to
surmount these challenges andsurmount these challenges and
ultimately, improve the healthcareultimately, improve the healthcare
delivery system in the Philippines fordelivery system in the Philippines for
the benefit of the Filipino people.the benefit of the Filipino people.
FIP-WHO META Istanbul, Turkey September 5, 2009 15
Thank You!Thank You!

More Related Content

Viewers also liked

MeTA in Uganda
MeTA in UgandaMeTA in Uganda
MeTA in Uganda
MeTApresents
 
Applying human rights to advocacy campaigns for access to essential medicines...
Applying human rights to advocacy campaigns for access to essential medicines...Applying human rights to advocacy campaigns for access to essential medicines...
Applying human rights to advocacy campaigns for access to essential medicines...
MeTApresents
 
Governance, transparency and Accountability~ MeTA objectives, approaches and ...
Governance, transparency and Accountability~ MeTA objectives, approaches and ...Governance, transparency and Accountability~ MeTA objectives, approaches and ...
Governance, transparency and Accountability~ MeTA objectives, approaches and ...
MeTApresents
 
Importan Information About Reference Culture From WHO Good Practices For Phar...
Importan Information About Reference Culture From WHO Good Practices For Phar...Importan Information About Reference Culture From WHO Good Practices For Phar...
Importan Information About Reference Culture From WHO Good Practices For Phar...
Alat Alat Laboratorium [dot] com
 
Medicines Transparency Alliance (MeTA) : country progress and key lessons
Medicines Transparency Alliance (MeTA) : country progress and key lessonsMedicines Transparency Alliance (MeTA) : country progress and key lessons
Medicines Transparency Alliance (MeTA) : country progress and key lessons
MeTApresents
 
MeTA programme implementation, monitoring and reporting
MeTA programme implementation, monitoring and reportingMeTA programme implementation, monitoring and reporting
MeTA programme implementation, monitoring and reporting
MeTApresents
 
Access To Medicine
Access To MedicineAccess To Medicine
Access To Medicine
MeTApresents
 
InstantGMP Compliance Series - Managing Deviations for Improved Compliance
InstantGMP Compliance Series - Managing Deviations for Improved ComplianceInstantGMP Compliance Series - Managing Deviations for Improved Compliance
InstantGMP Compliance Series - Managing Deviations for Improved Compliance
InstantGMP™
 
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...
IHS
 
Good Manufacturing Practices
Good Manufacturing PracticesGood Manufacturing Practices
Good Manufacturing Practices
Jorge Torres
 

Viewers also liked (10)

MeTA in Uganda
MeTA in UgandaMeTA in Uganda
MeTA in Uganda
 
Applying human rights to advocacy campaigns for access to essential medicines...
Applying human rights to advocacy campaigns for access to essential medicines...Applying human rights to advocacy campaigns for access to essential medicines...
Applying human rights to advocacy campaigns for access to essential medicines...
 
Governance, transparency and Accountability~ MeTA objectives, approaches and ...
Governance, transparency and Accountability~ MeTA objectives, approaches and ...Governance, transparency and Accountability~ MeTA objectives, approaches and ...
Governance, transparency and Accountability~ MeTA objectives, approaches and ...
 
Importan Information About Reference Culture From WHO Good Practices For Phar...
Importan Information About Reference Culture From WHO Good Practices For Phar...Importan Information About Reference Culture From WHO Good Practices For Phar...
Importan Information About Reference Culture From WHO Good Practices For Phar...
 
Medicines Transparency Alliance (MeTA) : country progress and key lessons
Medicines Transparency Alliance (MeTA) : country progress and key lessonsMedicines Transparency Alliance (MeTA) : country progress and key lessons
Medicines Transparency Alliance (MeTA) : country progress and key lessons
 
MeTA programme implementation, monitoring and reporting
MeTA programme implementation, monitoring and reportingMeTA programme implementation, monitoring and reporting
MeTA programme implementation, monitoring and reporting
 
Access To Medicine
Access To MedicineAccess To Medicine
Access To Medicine
 
InstantGMP Compliance Series - Managing Deviations for Improved Compliance
InstantGMP Compliance Series - Managing Deviations for Improved ComplianceInstantGMP Compliance Series - Managing Deviations for Improved Compliance
InstantGMP Compliance Series - Managing Deviations for Improved Compliance
 
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...
 
Good Manufacturing Practices
Good Manufacturing PracticesGood Manufacturing Practices
Good Manufacturing Practices
 

Similar to Transparency and Pharmaceutical Practice from a MeTA Country

MeTA FIP workshop programme
MeTA FIP workshop programmeMeTA FIP workshop programme
MeTA FIP workshop programme
MeTApresents
 
Contribution of a world-class regulatory system to the future of the pharmace...
Contribution of a world-class regulatory system to the future of the pharmace...Contribution of a world-class regulatory system to the future of the pharmace...
Contribution of a world-class regulatory system to the future of the pharmace...
Irish Pharmaceutical Healthcare Association (IPHA)
 
Jignesh ich
Jignesh ichJignesh ich
Jignesh ich
jigs2163
 
ICH PPT
ICH PPTICH PPT
ICH GUIDELINES Q S E M & REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW CO...
ICH GUIDELINES  Q S E M & REGULATORY REQUIREMENTS  OF  EU, MHRA, TGA & ROW CO...ICH GUIDELINES  Q S E M & REGULATORY REQUIREMENTS  OF  EU, MHRA, TGA & ROW CO...
ICH GUIDELINES Q S E M & REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW CO...
RushikeshPalkar1
 
Medicines Transparency in Jordan
Medicines Transparency in JordanMedicines Transparency in Jordan
Medicines Transparency in Jordan
MeTApresents
 
Ich guidelines QSEM suraj seminar
Ich guidelines  QSEM suraj seminarIch guidelines  QSEM suraj seminar
Ich guidelines QSEM suraj seminar
Suraj Pund
 
Dr. ta presentatio
Dr. ta presentatioDr. ta presentatio
Dr. ta presentatio
arulmoli
 
Fundamental concept of regulatory affairs in pharmaceutical & biotechnology
Fundamental concept of regulatory affairs in pharmaceutical & biotechnologyFundamental concept of regulatory affairs in pharmaceutical & biotechnology
Fundamental concept of regulatory affairs in pharmaceutical & biotechnology
Hitendra Singh
 
Ich
IchIch
Medicines Transparency Alliance (MeTA) Jordan
Medicines Transparency Alliance (MeTA) JordanMedicines Transparency Alliance (MeTA) Jordan
Medicines Transparency Alliance (MeTA) Jordan
MeTApresents
 
The data and analytics of the new life sciences marketplace handout
The data and analytics of the new life sciences marketplace handoutThe data and analytics of the new life sciences marketplace handout
The data and analytics of the new life sciences marketplace handout
Frank Wartenberg
 
5th pharmacovigilance congregation 2013
5th pharmacovigilance congregation 20135th pharmacovigilance congregation 2013
5th pharmacovigilance congregation 2013
Deepak Raj (2,000+Connections)
 
Concept and structure of MeTA
Concept and structure of MeTAConcept and structure of MeTA
Concept and structure of MeTA
MeTApresents
 
Hanaa cv 1 dec 2017-v2
Hanaa cv   1 dec 2017-v2Hanaa cv   1 dec 2017-v2
Hanaa cv 1 dec 2017-v2
Hanaa Abdel-Maguid
 
Shortages of medicines originating from manufacturing
Shortages of medicines originating from manufacturingShortages of medicines originating from manufacturing
Shortages of medicines originating from manufacturing
European Industrial Pharmacists Group
 
Joint Rare Diseases / Orphan Medicinal Products Task Force
Joint Rare Diseases / Orphan Medicinal Products Task ForceJoint Rare Diseases / Orphan Medicinal Products Task Force
Joint Rare Diseases / Orphan Medicinal Products Task Force
Dutch Orphan Drug Network
 
Using mobile phones for nutrition surveillance a review of evidence
Using mobile phones for nutrition surveillance   a review of evidenceUsing mobile phones for nutrition surveillance   a review of evidence
Using mobile phones for nutrition surveillance a review of evidence
Dr Lendy Spires
 
WHO Contribution to impementing MeTA
WHO Contribution to impementing MeTAWHO Contribution to impementing MeTA
WHO Contribution to impementing MeTA
MeTApresents
 
MeTA and data disclosure
MeTA and data disclosureMeTA and data disclosure
MeTA and data disclosure
MeTApresents
 

Similar to Transparency and Pharmaceutical Practice from a MeTA Country (20)

MeTA FIP workshop programme
MeTA FIP workshop programmeMeTA FIP workshop programme
MeTA FIP workshop programme
 
Contribution of a world-class regulatory system to the future of the pharmace...
Contribution of a world-class regulatory system to the future of the pharmace...Contribution of a world-class regulatory system to the future of the pharmace...
Contribution of a world-class regulatory system to the future of the pharmace...
 
Jignesh ich
Jignesh ichJignesh ich
Jignesh ich
 
ICH PPT
ICH PPTICH PPT
ICH PPT
 
ICH GUIDELINES Q S E M & REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW CO...
ICH GUIDELINES  Q S E M & REGULATORY REQUIREMENTS  OF  EU, MHRA, TGA & ROW CO...ICH GUIDELINES  Q S E M & REGULATORY REQUIREMENTS  OF  EU, MHRA, TGA & ROW CO...
ICH GUIDELINES Q S E M & REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW CO...
 
Medicines Transparency in Jordan
Medicines Transparency in JordanMedicines Transparency in Jordan
Medicines Transparency in Jordan
 
Ich guidelines QSEM suraj seminar
Ich guidelines  QSEM suraj seminarIch guidelines  QSEM suraj seminar
Ich guidelines QSEM suraj seminar
 
Dr. ta presentatio
Dr. ta presentatioDr. ta presentatio
Dr. ta presentatio
 
Fundamental concept of regulatory affairs in pharmaceutical & biotechnology
Fundamental concept of regulatory affairs in pharmaceutical & biotechnologyFundamental concept of regulatory affairs in pharmaceutical & biotechnology
Fundamental concept of regulatory affairs in pharmaceutical & biotechnology
 
Ich
IchIch
Ich
 
Medicines Transparency Alliance (MeTA) Jordan
Medicines Transparency Alliance (MeTA) JordanMedicines Transparency Alliance (MeTA) Jordan
Medicines Transparency Alliance (MeTA) Jordan
 
The data and analytics of the new life sciences marketplace handout
The data and analytics of the new life sciences marketplace handoutThe data and analytics of the new life sciences marketplace handout
The data and analytics of the new life sciences marketplace handout
 
5th pharmacovigilance congregation 2013
5th pharmacovigilance congregation 20135th pharmacovigilance congregation 2013
5th pharmacovigilance congregation 2013
 
Concept and structure of MeTA
Concept and structure of MeTAConcept and structure of MeTA
Concept and structure of MeTA
 
Hanaa cv 1 dec 2017-v2
Hanaa cv   1 dec 2017-v2Hanaa cv   1 dec 2017-v2
Hanaa cv 1 dec 2017-v2
 
Shortages of medicines originating from manufacturing
Shortages of medicines originating from manufacturingShortages of medicines originating from manufacturing
Shortages of medicines originating from manufacturing
 
Joint Rare Diseases / Orphan Medicinal Products Task Force
Joint Rare Diseases / Orphan Medicinal Products Task ForceJoint Rare Diseases / Orphan Medicinal Products Task Force
Joint Rare Diseases / Orphan Medicinal Products Task Force
 
Using mobile phones for nutrition surveillance a review of evidence
Using mobile phones for nutrition surveillance   a review of evidenceUsing mobile phones for nutrition surveillance   a review of evidence
Using mobile phones for nutrition surveillance a review of evidence
 
WHO Contribution to impementing MeTA
WHO Contribution to impementing MeTAWHO Contribution to impementing MeTA
WHO Contribution to impementing MeTA
 
MeTA and data disclosure
MeTA and data disclosureMeTA and data disclosure
MeTA and data disclosure
 

More from MeTApresents

MeTA financial systems and reporting
MeTA financial systems and reportingMeTA financial systems and reporting
MeTA financial systems and reporting
MeTApresents
 
Priorities and milestones – The Philippines
Priorities and milestones – The PhilippinesPriorities and milestones – The Philippines
Priorities and milestones – The Philippines
MeTApresents
 
MeTA priorities and milestones in Peru
MeTA priorities and milestones in PeruMeTA priorities and milestones in Peru
MeTA priorities and milestones in Peru
MeTApresents
 
Jordan National Priorities And Milestones
Jordan National Priorities And MilestonesJordan National Priorities And Milestones
Jordan National Priorities And Milestones
MeTApresents
 
MeTA introduction
MeTA introductionMeTA introduction
MeTA introduction
MeTApresents
 
MeTA Core Principles
MeTA Core PrinciplesMeTA Core Principles
MeTA Core Principles
MeTApresents
 
MeTA priorities and milestones in Zambia
MeTA priorities and milestones in ZambiaMeTA priorities and milestones in Zambia
MeTA priorities and milestones in Zambia
MeTApresents
 
Data disclosure in Zambia
Data disclosure in ZambiaData disclosure in Zambia
Data disclosure in Zambia
MeTApresents
 
MeTA priorities and milestones in Uganda
MeTA priorities and milestones in UgandaMeTA priorities and milestones in Uganda
MeTA priorities and milestones in Uganda
MeTApresents
 
MeTA pilot countries support needs and recommendations
MeTA pilot countries support needs and recommendationsMeTA pilot countries support needs and recommendations
MeTA pilot countries support needs and recommendations
MeTApresents
 
Strengthening multi-stakeholder processes
Strengthening multi-stakeholder processesStrengthening multi-stakeholder processes
Strengthening multi-stakeholder processes
MeTApresents
 
Data disclosure in Jordan
Data disclosure in JordanData disclosure in Jordan
Data disclosure in Jordan
MeTApresents
 
MeTA International priorities and milestones
MeTA International priorities and milestonesMeTA International priorities and milestones
MeTA International priorities and milestones
MeTApresents
 
MeTA priorities and milestones in Ghana
MeTA priorities and milestones in GhanaMeTA priorities and milestones in Ghana
MeTA priorities and milestones in Ghana
MeTApresents
 
Data disclosure in Ghana
Data disclosure in GhanaData disclosure in Ghana
Data disclosure in Ghana
MeTApresents
 
Data disclosurein Kyrgyzstan
Data disclosurein KyrgyzstanData disclosurein Kyrgyzstan
Data disclosurein Kyrgyzstan
MeTApresents
 
MeTA evaluation and future
MeTA evaluation and futureMeTA evaluation and future
MeTA evaluation and future
MeTApresents
 
MeTA country guidance note
MeTA country guidance noteMeTA country guidance note
MeTA country guidance note
MeTApresents
 
Data disclosure in Ghana
Data disclosure in GhanaData disclosure in Ghana
Data disclosure in Ghana
MeTApresents
 
MeTA MSP workshop: Follow up activities - World Cafe
MeTA MSP workshop: Follow up activities - World CafeMeTA MSP workshop: Follow up activities - World Cafe
MeTA MSP workshop: Follow up activities - World Cafe
MeTApresents
 

More from MeTApresents (20)

MeTA financial systems and reporting
MeTA financial systems and reportingMeTA financial systems and reporting
MeTA financial systems and reporting
 
Priorities and milestones – The Philippines
Priorities and milestones – The PhilippinesPriorities and milestones – The Philippines
Priorities and milestones – The Philippines
 
MeTA priorities and milestones in Peru
MeTA priorities and milestones in PeruMeTA priorities and milestones in Peru
MeTA priorities and milestones in Peru
 
Jordan National Priorities And Milestones
Jordan National Priorities And MilestonesJordan National Priorities And Milestones
Jordan National Priorities And Milestones
 
MeTA introduction
MeTA introductionMeTA introduction
MeTA introduction
 
MeTA Core Principles
MeTA Core PrinciplesMeTA Core Principles
MeTA Core Principles
 
MeTA priorities and milestones in Zambia
MeTA priorities and milestones in ZambiaMeTA priorities and milestones in Zambia
MeTA priorities and milestones in Zambia
 
Data disclosure in Zambia
Data disclosure in ZambiaData disclosure in Zambia
Data disclosure in Zambia
 
MeTA priorities and milestones in Uganda
MeTA priorities and milestones in UgandaMeTA priorities and milestones in Uganda
MeTA priorities and milestones in Uganda
 
MeTA pilot countries support needs and recommendations
MeTA pilot countries support needs and recommendationsMeTA pilot countries support needs and recommendations
MeTA pilot countries support needs and recommendations
 
Strengthening multi-stakeholder processes
Strengthening multi-stakeholder processesStrengthening multi-stakeholder processes
Strengthening multi-stakeholder processes
 
Data disclosure in Jordan
Data disclosure in JordanData disclosure in Jordan
Data disclosure in Jordan
 
MeTA International priorities and milestones
MeTA International priorities and milestonesMeTA International priorities and milestones
MeTA International priorities and milestones
 
MeTA priorities and milestones in Ghana
MeTA priorities and milestones in GhanaMeTA priorities and milestones in Ghana
MeTA priorities and milestones in Ghana
 
Data disclosure in Ghana
Data disclosure in GhanaData disclosure in Ghana
Data disclosure in Ghana
 
Data disclosurein Kyrgyzstan
Data disclosurein KyrgyzstanData disclosurein Kyrgyzstan
Data disclosurein Kyrgyzstan
 
MeTA evaluation and future
MeTA evaluation and futureMeTA evaluation and future
MeTA evaluation and future
 
MeTA country guidance note
MeTA country guidance noteMeTA country guidance note
MeTA country guidance note
 
Data disclosure in Ghana
Data disclosure in GhanaData disclosure in Ghana
Data disclosure in Ghana
 
MeTA MSP workshop: Follow up activities - World Cafe
MeTA MSP workshop: Follow up activities - World CafeMeTA MSP workshop: Follow up activities - World Cafe
MeTA MSP workshop: Follow up activities - World Cafe
 

Recently uploaded

Text Book of Operation Theater Nursing OT Nursing
Text Book of Operation Theater Nursing OT NursingText Book of Operation Theater Nursing OT Nursing
Text Book of Operation Theater Nursing OT Nursing
BP KOIRALA INSTITUTE OF HELATH SCIENCS,, NEPAL
 
selllllllllllllllllllllllllllllllllllllllllllllll.pptx
selllllllllllllllllllllllllllllllllllllllllllllll.pptxselllllllllllllllllllllllllllllllllllllllllllllll.pptx
selllllllllllllllllllllllllllllllllllllllllllllll.pptx
Joebest8
 
symblephoron types etiology management.pptx
symblephoron types etiology management.pptxsymblephoron types etiology management.pptx
symblephoron types etiology management.pptx
mohammadsumairah
 
Prostatitis Severity- How to Determine if You Have Mild Symptoms.pptx
Prostatitis Severity- How to Determine if You Have Mild Symptoms.pptxProstatitis Severity- How to Determine if You Have Mild Symptoms.pptx
Prostatitis Severity- How to Determine if You Have Mild Symptoms.pptx
AmandaChou9
 
Respiratory system at glance- Neonatology
Respiratory system at glance- NeonatologyRespiratory system at glance- Neonatology
Respiratory system at glance- Neonatology
Dr. Habibur Rahim
 
PCD Pharma Franchise For Gynae Products | Infertility Range - Sarthi Life Sci...
PCD Pharma Franchise For Gynae Products | Infertility Range - Sarthi Life Sci...PCD Pharma Franchise For Gynae Products | Infertility Range - Sarthi Life Sci...
PCD Pharma Franchise For Gynae Products | Infertility Range - Sarthi Life Sci...
Sarthi Life Sciences
 
STRATEGIES FOR RATIONALISING/REDUCING CAESAREAN SECTION RATE BY USE OF "SION ...
STRATEGIES FOR RATIONALISING/REDUCING CAESAREAN SECTION RATE BY USE OF "SION ...STRATEGIES FOR RATIONALISING/REDUCING CAESAREAN SECTION RATE BY USE OF "SION ...
STRATEGIES FOR RATIONALISING/REDUCING CAESAREAN SECTION RATE BY USE OF "SION ...
Niranjan Chavan
 
Building a Strong Partnership with Your Medical Team
Building a Strong Partnership with Your Medical TeamBuilding a Strong Partnership with Your Medical Team
Building a Strong Partnership with Your Medical Team
bkling
 
Drug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptxDrug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptx
drebrahiim
 
THE REVIEW OF THE ENCYCLOPEDIA OF PURE MATERIA MEDICA.BHMS.MATERIA MEDICA.HOM...
THE REVIEW OF THE ENCYCLOPEDIA OF PURE MATERIA MEDICA.BHMS.MATERIA MEDICA.HOM...THE REVIEW OF THE ENCYCLOPEDIA OF PURE MATERIA MEDICA.BHMS.MATERIA MEDICA.HOM...
THE REVIEW OF THE ENCYCLOPEDIA OF PURE MATERIA MEDICA.BHMS.MATERIA MEDICA.HOM...
DRPREETHIJAMESP
 
SA Gastro Cure(pancreatic cancer treatment in india).pptx
SA Gastro Cure(pancreatic cancer treatment in india).pptxSA Gastro Cure(pancreatic cancer treatment in india).pptx
SA Gastro Cure(pancreatic cancer treatment in india).pptx
VinothKumar70905
 
Article - Design and evaluation of novel inhibitors for the treatment of clea...
Article - Design and evaluation of novel inhibitors for the treatment of clea...Article - Design and evaluation of novel inhibitors for the treatment of clea...
Article - Design and evaluation of novel inhibitors for the treatment of clea...
Trustlife
 
Care and Maintenance of Laboratory Equipment in Histotechnology.pptx
Care and Maintenance of Laboratory Equipment in Histotechnology.pptxCare and Maintenance of Laboratory Equipment in Histotechnology.pptx
Care and Maintenance of Laboratory Equipment in Histotechnology.pptx
Dr. Jagroop Singh
 
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
ailynolive
 
Lymphoma Made Easy , New Teaching Lectures
Lymphoma Made Easy , New Teaching LecturesLymphoma Made Easy , New Teaching Lectures
Lymphoma Made Easy , New Teaching Lectures
MiadAlsulami
 
2024 07 12 Do you share my autistic traits_ - Google Sheets.pdf
2024 07 12 Do you share my autistic traits_ - Google Sheets.pdf2024 07 12 Do you share my autistic traits_ - Google Sheets.pdf
2024 07 12 Do you share my autistic traits_ - Google Sheets.pdf
CarriePoppy
 
High Girls Call Ranchi 000XX00000 Provide Best And Top Girl Service And No1 i...
High Girls Call Ranchi 000XX00000 Provide Best And Top Girl Service And No1 i...High Girls Call Ranchi 000XX00000 Provide Best And Top Girl Service And No1 i...
High Girls Call Ranchi 000XX00000 Provide Best And Top Girl Service And No1 i...
hf66550
 
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptxPICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
Aloy Okechukwu Ugwu
 
Types of Hypoxia, Hypercapnia, and Cyanosis
Types of Hypoxia, Hypercapnia, and CyanosisTypes of Hypoxia, Hypercapnia, and Cyanosis
Types of Hypoxia, Hypercapnia, and Cyanosis
MedicoseAcademics
 
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
Anindya Das Adhikary
 

Recently uploaded (20)

Text Book of Operation Theater Nursing OT Nursing
Text Book of Operation Theater Nursing OT NursingText Book of Operation Theater Nursing OT Nursing
Text Book of Operation Theater Nursing OT Nursing
 
selllllllllllllllllllllllllllllllllllllllllllllll.pptx
selllllllllllllllllllllllllllllllllllllllllllllll.pptxselllllllllllllllllllllllllllllllllllllllllllllll.pptx
selllllllllllllllllllllllllllllllllllllllllllllll.pptx
 
symblephoron types etiology management.pptx
symblephoron types etiology management.pptxsymblephoron types etiology management.pptx
symblephoron types etiology management.pptx
 
Prostatitis Severity- How to Determine if You Have Mild Symptoms.pptx
Prostatitis Severity- How to Determine if You Have Mild Symptoms.pptxProstatitis Severity- How to Determine if You Have Mild Symptoms.pptx
Prostatitis Severity- How to Determine if You Have Mild Symptoms.pptx
 
Respiratory system at glance- Neonatology
Respiratory system at glance- NeonatologyRespiratory system at glance- Neonatology
Respiratory system at glance- Neonatology
 
PCD Pharma Franchise For Gynae Products | Infertility Range - Sarthi Life Sci...
PCD Pharma Franchise For Gynae Products | Infertility Range - Sarthi Life Sci...PCD Pharma Franchise For Gynae Products | Infertility Range - Sarthi Life Sci...
PCD Pharma Franchise For Gynae Products | Infertility Range - Sarthi Life Sci...
 
STRATEGIES FOR RATIONALISING/REDUCING CAESAREAN SECTION RATE BY USE OF "SION ...
STRATEGIES FOR RATIONALISING/REDUCING CAESAREAN SECTION RATE BY USE OF "SION ...STRATEGIES FOR RATIONALISING/REDUCING CAESAREAN SECTION RATE BY USE OF "SION ...
STRATEGIES FOR RATIONALISING/REDUCING CAESAREAN SECTION RATE BY USE OF "SION ...
 
Building a Strong Partnership with Your Medical Team
Building a Strong Partnership with Your Medical TeamBuilding a Strong Partnership with Your Medical Team
Building a Strong Partnership with Your Medical Team
 
Drug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptxDrug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptx
 
THE REVIEW OF THE ENCYCLOPEDIA OF PURE MATERIA MEDICA.BHMS.MATERIA MEDICA.HOM...
THE REVIEW OF THE ENCYCLOPEDIA OF PURE MATERIA MEDICA.BHMS.MATERIA MEDICA.HOM...THE REVIEW OF THE ENCYCLOPEDIA OF PURE MATERIA MEDICA.BHMS.MATERIA MEDICA.HOM...
THE REVIEW OF THE ENCYCLOPEDIA OF PURE MATERIA MEDICA.BHMS.MATERIA MEDICA.HOM...
 
SA Gastro Cure(pancreatic cancer treatment in india).pptx
SA Gastro Cure(pancreatic cancer treatment in india).pptxSA Gastro Cure(pancreatic cancer treatment in india).pptx
SA Gastro Cure(pancreatic cancer treatment in india).pptx
 
Article - Design and evaluation of novel inhibitors for the treatment of clea...
Article - Design and evaluation of novel inhibitors for the treatment of clea...Article - Design and evaluation of novel inhibitors for the treatment of clea...
Article - Design and evaluation of novel inhibitors for the treatment of clea...
 
Care and Maintenance of Laboratory Equipment in Histotechnology.pptx
Care and Maintenance of Laboratory Equipment in Histotechnology.pptxCare and Maintenance of Laboratory Equipment in Histotechnology.pptx
Care and Maintenance of Laboratory Equipment in Histotechnology.pptx
 
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
Verified Girls Call Mumbai 🎈🔥9930687706 🔥💋🎈 Provide Best And Top Girl Service...
 
Lymphoma Made Easy , New Teaching Lectures
Lymphoma Made Easy , New Teaching LecturesLymphoma Made Easy , New Teaching Lectures
Lymphoma Made Easy , New Teaching Lectures
 
2024 07 12 Do you share my autistic traits_ - Google Sheets.pdf
2024 07 12 Do you share my autistic traits_ - Google Sheets.pdf2024 07 12 Do you share my autistic traits_ - Google Sheets.pdf
2024 07 12 Do you share my autistic traits_ - Google Sheets.pdf
 
High Girls Call Ranchi 000XX00000 Provide Best And Top Girl Service And No1 i...
High Girls Call Ranchi 000XX00000 Provide Best And Top Girl Service And No1 i...High Girls Call Ranchi 000XX00000 Provide Best And Top Girl Service And No1 i...
High Girls Call Ranchi 000XX00000 Provide Best And Top Girl Service And No1 i...
 
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptxPICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
 
Types of Hypoxia, Hypercapnia, and Cyanosis
Types of Hypoxia, Hypercapnia, and CyanosisTypes of Hypoxia, Hypercapnia, and Cyanosis
Types of Hypoxia, Hypercapnia, and Cyanosis
 
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
Amygdala Medi-Trivia Quiz (Prelims) | FAQ 2024
 

Transparency and Pharmaceutical Practice from a MeTA Country

  • 1. FIP-WHO META Istanbul, Turkey September 5, 2009 1 Normita D. Leyesa, RPh, MS President, Philippine Pharmacists Association MeTA Council Member Transparency and PharmaceuticalTransparency and Pharmaceutical Practice from a MeTA Country:Practice from a MeTA Country: The MeTA Philippines Country ReportThe MeTA Philippines Country Report 1
  • 2. FIP-WHO META Istanbul, Turkey September 5, 2009 2 Medicine Transparency AllianceMedicine Transparency Alliance (MeTA) initiative proposes to(MeTA) initiative proposes to improve accessimprove access to medicinesto medicines throughthrough transparencytransparency andand accountabilityaccountability..
  • 3. FIP-WHO META Istanbul, Turkey September 5, 2009 33 The Philippines WorkThe Philippines Work Plan for the Phase IPlan for the Phase I 2009-20102009-2010 Objective:Objective: Provide adequate information that would strengthen decision-making and implementation of processes along the medicines registration, selection, procurement, and use.
  • 4. FIP-WHO META Istanbul, Turkey September 5, 2009 4 Preparation ofPreparation of the Work Planthe Work Plan  Identification of priority areas for MeTAIdentification of priority areas for MeTA intervention by scoping visits, consultations, andintervention by scoping visits, consultations, and stakeholder mappingstakeholder mapping  Identification of areas supported by otherIdentification of areas supported by other international development partners andinternational development partners and stakeholdersstakeholders  Line-up of activities and allocated budget wereLine-up of activities and allocated budget were finally deliberated and approvedfinally deliberated and approved
  • 5. FIP-WHO META Istanbul, Turkey September 5, 2009 5 Three Key Points ofThree Key Points of Phase IPhase I 1.1. Country structure and commitmentCountry structure and commitment 2.2. Transparency: disclosure, data collectionTransparency: disclosure, data collection and analysisand analysis 3.3. Accountability: multi-stakeholderAccountability: multi-stakeholder approach and good governanceapproach and good governance
  • 6. FIP-WHO META Istanbul, Turkey September 5, 2009 6 2009-20102009-2010 Strategic Work PlanStrategic Work Plan  Developing Information on Prices, Availability,Developing Information on Prices, Availability, Financing Mechanisms and Rational Drug UseFinancing Mechanisms and Rational Drug Use  Generating Information to Improve Quality ofGenerating Information to Improve Quality of PharmaceuticalsPharmaceuticals  Setting up Systems for Transparency in MedicinesSetting up Systems for Transparency in Medicines Registration, Selection, Procurement and UsageRegistration, Selection, Procurement and Usage  Supporting Transparency Agenda in DecentralizedSupporting Transparency Agenda in Decentralized SystemsSystems  Preparation of Budget for the ActivitiesPreparation of Budget for the Activities
  • 7. FIP-WHO META Istanbul, Turkey September 5, 2009 7 KEY OUTCOMESKEY OUTCOMES
  • 8. FIP-WHO META Istanbul, Turkey September 5, 2009 8 Key Outcome 1:Key Outcome 1: Available information onAvailable information on medicines quality, registration,medicines quality, registration, access, promotions, and rationalaccess, promotions, and rational drug usedrug use  Analysis of existing pharmaceutical data (ongoing)Analysis of existing pharmaceutical data (ongoing)  Conduct of Level II and III Survey on medicinesConduct of Level II and III Survey on medicines (ongoing)(ongoing)  Assessment of Public SectorAssessment of Public Sector – Procurement (including PITC) of medicinesProcurement (including PITC) of medicines – Design ofDesign of ee-procurement system-procurement system – Assessment of the current systems for financingAssessment of the current systems for financing medicines for the poor (TOR)medicines for the poor (TOR)  Survey of quality of medicines using the “FDA in aSurvey of quality of medicines using the “FDA in a suitcase”suitcase”  Study on medicines promotion and advertisementStudy on medicines promotion and advertisement (TOR)(TOR)
  • 9. FIP-WHO META Istanbul, Turkey September 5, 2009 9 Key Outcome 2:Key Outcome 2: Setting up of informationSetting up of information structures and systemsstructures and systems  Improvement of the medicines registrationImprovement of the medicines registration  FDA websiteFDA website  Philippine National Drug Formulary WebsitePhilippine National Drug Formulary Website  Support to the implementation of the ElectronicSupport to the implementation of the Electronic Essential Drug Price Monitoring System (E-EDPMS) atEssential Drug Price Monitoring System (E-EDPMS) at the regional and provincial levelsthe regional and provincial levels  Development of systems for monitoring andDevelopment of systems for monitoring and evaluation of ethical practices of industry and theevaluation of ethical practices of industry and the medical professionmedical profession  Development and testing of monitoring tools forDevelopment and testing of monitoring tools for prescription auditsprescription audits
  • 10. FIP-WHO META Istanbul, Turkey September 5, 2009 10 Key Outcome 3:Key Outcome 3: Improvement of technicalImprovement of technical capacity for disclosure, analysis, andcapacity for disclosure, analysis, and the use of information and evidencethe use of information and evidence  Pharmaceutical Management and Good GovernancePharmaceutical Management and Good Governance Course for LGU Health Managers and Local ChiefCourse for LGU Health Managers and Local Chief ExecutivesExecutives  National Good Governance in Medicines AwardsNational Good Governance in Medicines Awards  Strengthening of Drug Therapeutic Committees (DTC) atStrengthening of Drug Therapeutic Committees (DTC) at Regional and Provincial levelsRegional and Provincial levels  Technical capacity building for DTCsTechnical capacity building for DTCs  Development of tools for monitoring/evaluation of DTCsDevelopment of tools for monitoring/evaluation of DTCs  Piloting of the Pharmaceutical Bench BookPiloting of the Pharmaceutical Bench Book
  • 11. FIP-WHO META Istanbul, Turkey September 5, 2009 11 Key Outcome 4:Key Outcome 4: Setting up mechanism forSetting up mechanism for advocacy and participation inadvocacy and participation in decision making processesdecision making processes  MeTA Roundtable discussionsMeTA Roundtable discussions  PublicationsPublications – Development of the MeTA WebsiteDevelopment of the MeTA Website – Publication of Proceedings for MeTA ForumPublication of Proceedings for MeTA Forum – Publication of Baseline AssessmentsPublication of Baseline Assessments  Annual MeTA ForumAnnual MeTA Forum
  • 12. FIP-WHO META Istanbul, Turkey September 5, 2009 12 Key Outcome 5:Key Outcome 5: Sustaining a Multi-stakeholderSustaining a Multi-stakeholder CollaborationCollaboration  MeTA Council and Secretariat OperationsMeTA Council and Secretariat Operations  Support to Civil Society OrganizationsSupport to Civil Society Organizations – Coalition for Health Advocacy and TransparencyCoalition for Health Advocacy and Transparency
  • 13. FIP-WHO META Istanbul, Turkey September 5, 2009 13 ““The challenges in transparency andThe challenges in transparency and accountability on medicine registration,accountability on medicine registration, selection, procurement, and use in theselection, procurement, and use in the Philippines are enormous.Philippines are enormous. These can be summed up into two:These can be summed up into two: non-non- accessibility of dataaccessibility of data to policy, decisionto policy, decision makers, and consumers and themakers, and consumers and the lack oflack of tools and structurestools and structures for adequatefor adequate reporting, disclosure and feedback.”reporting, disclosure and feedback.”
  • 14. FIP-WHO META Istanbul, Turkey September 5, 2009 14 With the assistance of MeTAWith the assistance of MeTA International, and the Department ofInternational, and the Department of International Development (DFID) UK,International Development (DFID) UK, and the support of the World Healthand the support of the World Health Organization, we will be able toOrganization, we will be able to surmount these challenges andsurmount these challenges and ultimately, improve the healthcareultimately, improve the healthcare delivery system in the Philippines fordelivery system in the Philippines for the benefit of the Filipino people.the benefit of the Filipino people.
  • 15. FIP-WHO META Istanbul, Turkey September 5, 2009 15 Thank You!Thank You!